Modeling Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention

Richard J. Drake*1,2, Merete Nordentoft3, Gillian Haddock2,4, Celso Arango5, W. Wolfgang Fleischhacker6, Birte Glenthøj7, Marion Leboyer8, Stefan Leucht9, Markus Leweke10, Phillip McGuire11, Andreas Meyer-Lindenberg10, Dan Rujescu12,13, Iris E. Sommer14, René S. Kahn14, and Shon W. Lewis*1,2

1Manchester Academic Health Sciences Centre, Institute of Brain, Behaviour & Mental Health, University of Manchester, Manchester, UK; 2Manchester Academic Health Sciences Centre, Manchester Mental Health & Social Care NHS Trust, Manchester, UK; 3Mental Health Centre Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen NV, Denmark; 4Manchester Academic Health Sciences Centre, School of Psychological Sciences, University of Manchester, Manchester, UK; 5Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; 6Department of Psychiatry and Psychotherapy, Medical University Innsbruck, Innsbruck, Austria; 7Center for Neuropsychiatric Schizophrenia Research and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Psychiatric Hospital Center Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark; 8INSERM U955, Laboratoire Psychopathologie et génétique des maladies mentales, et AP-HP, DHU Pe-PSY, Pole de Psychiatrie et d’addictologie des Hôpitaux Universitaires Henri Mondor, Université Paris-Est, Créteil, France; 9Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany; 10Central Institute of Mental Health, Mannheim, Germany; 11King’s College London, Institute of Psychiatry, London, UK; 12Psychiatry, Molecular and Clinical Neurobiology, Ludwig-Maximilians University, München, München, Germany; 13Department of Psychiatry, University of Halle, Halle, Germany; 14Department of Psychiatry, Brain Center Rudolf Magnus, UMC Utrecht, Utrecht, The Netherlands

*To whom correspondence should be addressed: University of Manchester, 3.315 Jean McFarlane Building, Oxford Road, Manchester M13 9PL, UK; tel: +44-161-306-7943, fax: +44-161-306-7946, e-mail: richard.drake@manchester.ac.uk

We aimed to design a multimodal intervention to improve adherence following first episode psychosis, consistent with current evidence. Existing literature identified medication attitudes, insight, and characteristics of support as important determinants of adherence to medication: we examined medication attitudes, self-esteem, and insight in an early psychosis cohort better to understand their relationships. Existing longitudinal data from 309 patients with early Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, nonaffective psychosis (83% first episode) were analyzed to test the hypothesis that medication attitudes, while meaningfully different from “insight,” correlated with insight and self-esteem, and change in each influenced the others. Rosenberg Self-Esteem Scale, Birchwood Insight Scale, and Positive and Negative Syndrome Scale insight were assessed at presentation, after 6 weeks and 3 and 18 months. Drug Attitudes Inventory (DAI) and treatment satisfaction were rated from 6 weeks onward. Structural equation models of their relationships were compared. Insight measures’ and DAI’s predictive validity were compared against relapse, readmission, and remission. Analysis found five latent constructs best fitted the data: medication attitudes, self-esteem, accepting need for treatment, self-rated insight, and objective insight. All were related and each affected the others as it changed, except self-esteem and medication attitudes. Low self-reported insight at presentation predicted readmission. Good 6-week insight (unlike drug attitudes) predicted remission. Literature review and data modeling indicated that a multimodal intervention using motivational interviewing, online psychoeducation, and SMS text medication reminders to enhance adherence without damaging self-concept was feasible and appropriate.

Key words: insight/self-esteem/schizophrenia/first episode/mHealth/web-based/adherence

Introduction

Poor adherence to antipsychotics is a major cause of psychotic relapse. Interventions to improve adherence are becoming more sophisticated1 as many of its determinants become clearer.2 Nevertheless, therapeutic successes have been limited and much of this complex, multidetermined behavior remains enigmatic. The argument that early psychosis forms a critical period that shapes later prognosis3,4—partly because attitudes to...
illness and treatment are still developing that will evolve to shape later behavior.5–7—in turn suggests that intervention during this window might succeed better.

Recent evidence-based guidelines for developing such complex interventions8 emphasize the importance of literature review to provide some theoretical rationale, followed by “modeling” of key processes, the feasibility and acceptability of potential interventions’ elements (separately or combined), and a potential trial before trialing and further evaluation.

This article will examine (1) how far the complex frameworks developed to explain nonadherence in chronic schizophrenia are supported by recent studies in first episode psychosis, (2) how far and how quickly key processes related to nonadherence interact and change in an acutely presenting first episode cohort followed over the medium term, (3) why combining interventions, is likely to be the most effective approach to a randomized trial of intervention, and (4) feasibility of the interventions selected within the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) program.9

Determinants of Poor Adherence in Early Schizophrenia

There is increasing evidence, with some gaps, that explanatory frameworks for nonadherence derived from studies in chronic disorder apply to early schizophrenia. The most proximal predictors influence the act of taking medication by altering its delivery and availability, support for/monitoring of administration, or patients’ attitudes to medication.

1. Antipsychotic formulation. Long acting injectable (LAI) formulations have equivocal impact on outcome compared with oral medication in randomized trials11 although these often suffer methodological difficulties such as selection bias against the nonadherent.12 LAIs have as much as halved relapse hazard in large prospective cohort studies,13,14 including after first admission in a national case register study.15 Despite these advantages, they are not often used first line, in part because there are few trials after first episodes16 and because of concerns about acceptability.17

2. Social and professional support. Adherence in chronic schizophrenia is influenced by setting (eg, supported accommodation) and reminders (eg, from diaries, adherence aids, and staff).18–21 Information technology–based interventions are discussed below. Family support is important in young patients in first episode services,22,23 but little other recent work specific to early schizophrenia focuses on setting, support, and adherence.

3. Engagement with services. Integration of a psychotic episode into self-concept after early psychotic episodes, as opposed to “sealing over” or “isolation” that involves denying its future relevance,45 predicts better early engagement but not adherence.46,47 Supporting decision making enhances satisfaction and may provide a sense of control that supports integration (and may affect attitudes to medication) but again does not seem directly to impact adherence.48 However, disengagement will cause unmeasured nonadherence, data from such lost patients being missing, leaving its impact underestimated. Some cohort analyses exclude such patients14,43,49–51 and they are unlikely to enter
Difficult accessing services has also been posited as affecting adherence and engagement in chronic
disease and in early psychosis, but there is no evidence from existing studies, albeit mostly conducted in early intervention services where active engagement of services with patients is emphasized. This appears more important than access. Properly coordinated follow-up after discharge influences adherence and the early intervention model probably reduces relapse partly by improving adherence.

4. Neurocognitive deficits. Their impact varies in early psychosis: some studies find low premorbid and executive cognitive function predicts early adherence, but others do not; there is no consistent general effect. Neurocognitive deficits that predict medication mismanagement in chronic illness (eg, prospective, working memory, learning, and comprehension) predict more general self-management difficulty, so such deficits might therefore necessitate more support, improving adherence. Paradoxically, some out-patients with partial adherence might intend concordance but fail neurocognitively, while those not adhering with better cognition may have made a decision to stop antipsychotics. Of course, forgetting medication is common across disorders.

5. Attitudes to medication. These attitudes are consistently important predictors when assessed in early illness, even when potential proxies such as detention or initial medication refusal are included; overall hostility predicts negative attitudes and poor early adherence. Occasional studies find that attitudes are not predictive. The timing of their “baseline” assessments may be critical for assessing their longitudinal effect because attitudes and adherence are dynamic in early psychosis.

Because variables directly predicting attitudes to medication in early psychosis appear to be fluid and so potentially amenable to change, it is worth considering what influences them:

1. Perceived benefit of treatment. There is evidence in early illness that actual benefit is important and that patients test this with antipsychotic “holidays” to see if symptoms re-emerge. Reactance, the disposition to reverse perceived losses of autonomy, affects perceived benefit as does insight, especially recognizing symptoms during first episodes. However, there appears an independent effect of perceived benefit too. Impaired cognition might reduce the capacity to detect beneficial changes even where it does not directly determine adherence. Metacognition (the ability to cognitively “step back,” and in this context consider medication’s effect on symptoms) appears to affect insight after first episodes and later adherence.

2. Perceived risk. Successful frameworks identify both fear of consequences of relapse (presumably related to awareness of current and past consequences of illness) and recognition of the likelihood of relapse.

3. Insight and self-concept. Scores on the Drug Attitudes Inventory (DAI), the most used instrument to assess attitudes to medication, are affected by key attitudes to symptoms, illness, and self. Many studies in early psychosis show insight to be a major predictor of nonadherence and discontinuation but its effect may be indirect. Various studies find no direct effect of insight on adherence, but they include potential mediators in their models: eg, attitudes, detention, or initial medication refusal; arguably, duration of untreated psychosis and continued substance misuse.

Common social stereotypes shape attitudes to disorder and treatment, which appear important determinants of not only acceptance of illness, perceived risk, and hence adherence but also self-esteem, self-stigmatization, and depression in early psychosis. The latter’s qualitative study confirmed that awareness of a first episode could be integrated or isolated (“sealed over,” as above). This is consistent with data from chronic illness showing that negative stereotypes only affected morale if accepted as applicable to oneself, and some evidently have good insight without self-stigmatization, but these processes explain resistance to change in some patients.

Sealing over can be seen as a maladaptive response to cognitive dissonance between self-concept and awareness of illness that requires a change in schemata to resolve. Adherence attitudes have also been described in terms of the “stages of change” model. The same model is used for substance misuse, often a comorbid problem. Common themes of decision-making capacity and motivation to continue healthy behavior in the face of ambivalence are relevant to cognitive intervention in both types of disorder. Stopping cannabis was associated with improved adherence in one first episode cohort.

4. Prescribing alliance and significant others. For adherence in chronic illness, relationship with prescribers seems to be by far the most important relationship with services. It in turn influences attitudes to medication, but internal locus of control may moderate the effect of significant others on attitudes and adherence. Highly autonomous individuals may be more or less adherent depending on their adherence style; their views are less influenced by others one way or the other. These processes are relevant in early illness: Haley et al confirmed that the more powerful others’ views were felt to be, the more positive medication attitudes 6 weeks and 18 months after first presentation. Montreuil et al found that key worker alliance also predicted later adherence, whether staff or patient rated.
Family and peer relationships might be important. Family members skeptical of medication and treatment may have a corrosive effect,\textsuperscript{54} which in early illness appears dynamic, depending on contact and family function.\textsuperscript{43} Consistent with this is the positive effect of family intervention on adherence and relapse in chronic illness,\textsuperscript{2} even with 8 weeks of family psychoeducation.\textsuperscript{88}

\textbf{5. Side effects.} Although it is implausible that, say, erectile dysfunction in young men or weight gain in young women have no effect on adherence,\textsuperscript{10,30,89-91} overall ratings of objective or subjective adverse effects have failed consistently to predict adherence in early illness.\textsuperscript{12,22,58,63,66} The Health Beliefs Model\textsuperscript{92} suggests that given the seriousness of the illness, if one perceives antipsychotics’ value one will tolerate many adverse effects.

Existing literature therefore suggests that—apart from medication formulation and the nature of and relationships with support—neurocognitive deficits, attitudes to medication, and insight make natural targets for adherence interventions. However, understanding when and how to shift attitudes and insight without consequent demoralization and long-term dysfunction\textsuperscript{76,93-95} is critical.

\textit{Modeling Drug Attitudes and Insight in Early Schizophrenia}

Much of the growing body of evidence about insight and treatment attitudes in early psychosis cohorts relies on samples assessed potentially weeks after presentation, when the peak of initial psychosis has passed. They often use methods unsuited to reveal the full complexity of potential interactions, important in understanding how interventions might be constructed to target multiple processes when they are at their most tractable.

We investigated attitudes to medication, insight, and self-esteem, though not adherence, in a cohort of 309 patients. They were recruited within 2 weeks of consecutive presentations with first ($n = 257, 83\%$) or second ($n = 52$) episode nonaffective psychosis. They were originally randomized to Cognitive Behavioral Therapy for psychosis, supportive counseling or treatment as usual\textsuperscript{96,97} before repeated assessments over 18 months.

Insight, attitudes, and self-esteem can display trait-like characteristics or state-driven ones (eg, during acute episodes). Arguably intervention targets should display sufficient change to indicate malleability but sufficient stability to envisage lasting change. Review reveals medication attitudes to be dynamic, though some predictors are relatively stable. Some argue that insight is trait like,\textsuperscript{7} yet if first assessed sufficiently early one might expect it to improve as symptoms resolve.\textsuperscript{80} If insight and attitudes change, scores after response should be more predictive of relapse, readmission, and remission than initial attitudes, contrary to some previous data.\textsuperscript{52,64,80} Both trait-like and state-driven aspects were evidenced in a stable, early psychosis group.\textsuperscript{98}

Self-esteem during acute initial psychosis is usually studied retrospectively.\textsuperscript{81-83} A prospective, longitudinal study starting from presentation ignored its trajectory and effect on attitudes.\textsuperscript{5} Notably, in later psychosis positive self-evaluation predicts integration rather than sealing over (which may nevertheless avoid depression).\textsuperscript{99}

How far medication attitudes and different aspects of insight (eg, awareness of illness, recognizing symptoms as such, accepting a need for treatment\textsuperscript{100}) reflect separate constructs rather than common schemata, even in the earliest stages of psychosis, is also important. Implicit in those studies that assess both,\textsuperscript{50,52,72} it has not been examined. Nor is it clear how far different aspects of insight differ in their effect on self-concept. If they differ and are separable, it might be possible to improve some aspects of concordance or insight without damaging self-concept.

We proposed to examine four hypotheses.

1. Attitudes to medication and the various aspects of insight reflect separate underlying constructs.
2. All aspects of insight, reflecting a common construct, cross-sectionally correlate with self-esteem and medication attitudes, good insight correlating with low self-esteem and concordant attitudes.
4. These variables all display rapid initial improvement and then stability, ie, state and trait characteristics.

\textbf{Methods}

Participants were recruited from consecutive presentations with first and second episodes (within 2 years of the first) of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophrenia, schizoaffective disorder, schizophreniform disorder, schizotypal disorder, “psychosis not otherwise specified” from geographically defined catchments (procedures detailed elsewhere\textsuperscript{96,97}). Self-esteem was assessed with the Rosenberg Self-Esteem Scale,\textsuperscript{101} insight with Birchwood’s self-rated Insight Scale (BIS)\textsuperscript{102} and the assessor rated Positive and Negative Syndrome Scale (PANSS)\textsuperscript{103} insight item, g12, at presentation, 6 weeks, 3 months, and 18 months later. The Insight Scale has three subscales: relabeling symptoms, awareness of illness, and recognizing the need for treatment.\textsuperscript{102}

Satisfaction with treatment (rated on a 10-cm visual analog scale by participants) and Drug Attitude Inventory (DAI\textsuperscript{79}) were rated at 6 weeks and each succeeding visit.

The pattern of missing data was analyzed by entering completion of each scale at each stage into a series of binary logistic regressions with baseline sex, age at onset,
ethnic group, diagnosis, substance dependence, education, and center as independent variables.

These data were included in various structural equation models (with AMOS 20.0\textsuperscript{104}). A series of models and assumptions were tested cross-sectionally (see supplementary methods and supplementary table 2). Based on these, longitudinal models were constructed: first to model the development of coherent elements and then interactions across the whole variable set. Sensitivity analyses for the effect of center, sex, episode, and therapy were planned.

Attitudes' effect on outcome was assessed using receiver operating characteristic curves to predict relapse, readmission, and remission using SPSS 20.0.\textsuperscript{104} Readmission was recorded from case notes. Relapse was defined as a 2-week exacerbation of symptoms recorded in case notes and leading to a change in management. Remission by applying the symptomatic criteria of Andreasen et al\textsuperscript{105} at 18 months, without the time criterion. Curves were assessed using the area under the curve, and Fisher's exact test was used to compare performance of different cutoffs as predictors of outcomes. Potential cutoffs for comparison were selected as (1) furthest from the chance line, (2) nearest to coordinates of 100% sensitivity and 0% false negative, or (3) highest likelihood ratio.

Results

Patients were first assessed a median of 6 days after admission. Number followed-up, scores for the modeled variables, and PANSS are presented in table 1. Mean scores often changed little despite large variations in individuals' scores over time: DAI change scores were mean 1.7 and then 1.7 (effect sizes: $d = 0.15$ and 0.15), but corresponding SDs were 9.8 and 10.6.

Logistic regression showed that while “center” frequently predicted that data for various scales were missing, no other variables did. Data were therefore “missing at random” in Little and Rubin’s\textsuperscript{106} classification (supplementary table 1).

Cross-sectional Models of Medication Attitudes, Self-esteem, and Insight

Models of scores for Rosenberg Self-Esteem, BIS subscales, DAI, and satisfaction at each stage of follow-up were compared against criteria for fit and parsimony described in table 2. Although models with three latent variables—Insight, Self-Esteem, and Medication Attitudes—fitted adequately (supplementary methods and supplementary table 2), longitudinal models (below) showed that five latent constructs—Objective Insight, Self-Reported Insight, Self-Esteem, Medication Attitudes, and Need for Treatment—were necessary to explain longitudinal changes in scores. Cross-sectional models based on longitudinal model M6 (below) also fitted adequately (table 2 and figure 1), apart from marginal fit at 18 months. Though the constructs were clearly separable, supporting Hypothesis 1, the aspects of insight neither reflected a common factor nor were equally related to self-esteem, disconfirmed Hypothesis 2.

Simple Longitudinal Models

Growth curve models were fitted separately for Self-Esteem, Insight, and Medication Attitudes (supplementary figure 2). These included a latent constant (representing constant underlying Self-Esteem, Insight, or Attitudes) correlated with a latent change term (representing change across follow-up for each of these constructs). This fitted well for Self-Esteem (L3, table 2). Adequately fitting models for insight (L2) required latent “Objective Insight” constant and change variables to predict PANSS insight and latent “Self-Reported Insight” constant and change variables to predict Awareness of Illness (AWI) and Relabeling Symptoms (RLS). Latent Medication Attitudes constant

| Table 1. Mean (SD) Scores for Insight, Self-esteem, Drug Attitudes, and Symptoms |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| Variable (Potential Range)      | Baseline, $n = 309 (100\%)$ | 6 Weeks, $n = 236 (76\%)$ | 3 Months, $n = 218 (71\%)$ | 18 Months, $n = 225 (73\%)$ |
| PANSS insight (1–7)             | 4.41 (1.49)     | 3.26* (1.58)    | 3.10 (1.48)     | 3.04 (1.45)     |
| Relabeling symptoms (0–4)      | 2.30 (1.32)     | 2.85* (1.22)    | 2.81 (1.23)     | 2.71 (1.31)     |
| Awareness of illness (0–4)     | 1.96 (1.43)     | 2.00 (1.38)     | 2.00 (1.36)     | 2.05 (1.40)     |
| Need for treatment (0–4)       | 2.68 (1.15)     | 2.80 (1.12)     | 2.84 (1.06)     | 2.88 (1.19)     |
| Self-Esteem (10–40)            | 27.16 (4.82)    | 26.90 (4.71)    | 27.66 (4.19)    | 27.80 (4.42)    |
| DAI (~30 to +30)               | 7.06 (11.09)    | 7.88 (10.66)    | 9.50 (11.39)    |
| Satisfaction (0–10)            | 6.55 (2.82)     | 6.79 (2.40)     | 6.90 (2.75)     |
| PANSS positive (7–49)          | 23.4 (4.8)      | 15.1* (6.2)     | 13.0 (5.1)      | 13.7 (5.4)      |
| PANSS total (30–210)           | 88.0 (17.3)     | 67.5* (19.2)    | 62.2 (17.7)     | 62.1 (18.2)     |

Note: *Positive and Negative Symptom Scale.
\textsuperscript{a}Rosenberg Self-Esteem Scale.
\textsuperscript{b}Drug Attitudes Inventory.
\textsuperscript{c}Medication satisfaction.
*Significant change in score (paired $t$-test $P < .05$).
Adherence Determinants and Intervention

and change variables predicted DAI and Satisfaction, but Need For Treatment (NFT) scores required separate “Need for Treatment” latent constant and change variables (L1). Self-Esteem and Self-Reported Insight (as Hypothesis 4 predicted, unlike other latent change variables) fitted better if change scores were modeled on the basis of rapid initial change decelerating over follow-up, rather than linear change (supplementary methods).

Overall Longitudinal Models

These growth curve models were combined into overall models predicting all scale scores throughout follow-up (M2, table 2). All latent constants (Self-Esteem, Self-Reported and Objective Insight, Mediation Attitudes, and Need for Treatment) correlated with each other and all latent change scores correlated with each other, but each constant only correlated with its own change variable. Serial modifications were made to a sequence of models (M3–M6) to improve fit (supplementary table 2). In summary: (a) Self-Esteem and Awareness of Illness each predicted the other, (b) A WI predicted NFT, and (c) Self-Esteem latent change predicted A WI at each follow-up (cf figure 1). To generate the final model, M7, nonsignificant relationships were removed from M6 in sequence, least significant first, until M7’s overall fit significantly worsened.

In model M7, Rosenberg scores no longer consistently predicted A WI, though rising latent Self-Esteem always predicted poorer Awareness, and better Awareness always directly predicted higher Rosenberg score. Three-month Relabeling Symptoms was unaffected by insight change. All latent constants intercorrelated, and all change scores intercorrelated except “Self-esteem” and “Medication attitudes” (figure 2), only partly supporting Hypothesis 3. Neither of the insight latent constants correlated with their latent change scores.

Planned sensitivity analyses fitting M7 to various subpopulations (supplementary methods) produced common fit index scores >0.90 and root mean square

### Table 2. Comparison of Structural Equation Models

<table>
<thead>
<tr>
<th>Model</th>
<th>χ²</th>
<th>df</th>
<th>CFI</th>
<th>NNFI</th>
<th>RMSEA</th>
<th>AIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline: four-factor cross-sectional</td>
<td>7</td>
<td>3</td>
<td>0.98</td>
<td>0.92</td>
<td>0.068</td>
<td>41</td>
</tr>
<tr>
<td>6 weeks: five-factor cross-sectional</td>
<td>10</td>
<td>10</td>
<td>1.00</td>
<td>1.00</td>
<td>0.010</td>
<td>60</td>
</tr>
<tr>
<td>3 months: five-factor cross-sectional</td>
<td>9</td>
<td>6</td>
<td>0.99</td>
<td>0.95</td>
<td>0.037</td>
<td>66</td>
</tr>
<tr>
<td>18 months: five-factor cross-sectional</td>
<td>17</td>
<td>6</td>
<td>0.95</td>
<td>0.83</td>
<td>0.076</td>
<td>59</td>
</tr>
<tr>
<td>L1: satisfaction, DAI, NFT</td>
<td>43</td>
<td>23</td>
<td>0.94</td>
<td>0.89</td>
<td>0.053</td>
<td>105</td>
</tr>
<tr>
<td>L2: PANSS insight, RLS, A WI</td>
<td>83</td>
<td>46</td>
<td>0.95</td>
<td>0.92</td>
<td>0.051</td>
<td>171</td>
</tr>
<tr>
<td>L3: Rosenberg</td>
<td>0.2</td>
<td>1</td>
<td>1.00</td>
<td>1.04</td>
<td>0</td>
<td>26</td>
</tr>
<tr>
<td>M2: Combining L1, L2, L3</td>
<td>561</td>
<td>248</td>
<td>0.82</td>
<td>0.76</td>
<td>0.064</td>
<td>765</td>
</tr>
<tr>
<td>M6: M2 modified (see text)</td>
<td>385</td>
<td>229</td>
<td>0.91</td>
<td>0.87</td>
<td>0.047</td>
<td>627</td>
</tr>
<tr>
<td>M7: M6 with nonsignificant relationships removed</td>
<td>376</td>
<td>242</td>
<td>0.92</td>
<td>0.90</td>
<td>0.042</td>
<td>592</td>
</tr>
</tbody>
</table>

Note: Measures of fit and parsimony for various models of insight, self-esteem, and medication attitudes. Models for each cross-sectional stage, longitudinal growth curve models for specific groups of scales (L1–L3), and integrated longitudinal models combining all growth curves for all measures (M2, M6, and M7). CFI, Common Fit Index; RMSEA, root mean square error approximation; AIC, Akaike’s Information Criterion; AWI, Awareness of Illness, RLS, Relabeling Symptoms.

a Common fit index: scores <0.90 indicate a substantial improvement is possible.
b Non-normed fit index: scores <0.90 indicate a substantial improvement is possible.
c Root mean square error approximation: scores <0.100 adequate, <0.050 good.
d Akaike’s information criterion: low values indicate better fitted, moreparsimonious models.

Four latent variables: NFT, Self-Esteem, Self-Rated Insight, and Objective Insight (without Medication Attitudes because DAI and Satisfaction unmeasured at baseline).

Five latent variables: Medication Attitudes, NFT, Self-Esteem, Self-Rated Insight, and Objective Insight.

Growth curve model, latent constructs Medication Satisfaction and NFT.

Growth curve model, latent constructs Self-Rated and Objective Insight.

Growth curve model, latent constructs Self-Esteem.

### Figure 1.

Cross-sectional model of scale scores. This represents underlying objective assessment of insight, self-report of insight, self-esteem, acceptance of the need for treatment, and concordance with medication as predicting scores on a range of scales at each stage of follow-up.
Fig. 2. Relationships between latent variables in the longitudinal model M7. This represents relationships between latent constant and change variables within the model, for simplicity excluding their relationships to actual scale scores over follow-up.

Performance of Scales as Predictors of Outcome

Readmission was significantly predicted by poor baseline Birchwood Insight Scale scores (but not 6-week scores), 6-week PANSS insight (but not baseline), and poor concordance on 6-week DAI scores (supplementary table 2). Insight Scale cutoff < 6 performed best: \( P < .001 \); positive predictive value (PPV) 61%; negative predictive value (NPV) 72%. Relapse was more poorly predicted, only baseline Insight Scale being even trend significantly predictive \( (P = .068) \) and only Insight Scale cutoff <6 being significantly predictive \( (PPV 73\% \text{ and NPV } 65\% ; P = .039; \text{ supplementary table 3}) \).

DAI cutoff <4 was significant where the whole scale was not \( (PPV \text{ for relapse } 67\%, \text{ NPV } 56\%, P = .048) \).

Cross-sectional remission at final follow-up (supplementary table 4) was predicted by insight and PANSS score but not the overall DAI scale, though the best individual DAI cutoff (score \( \geq 0 \)) was significantly associated with remission \( (PPV 69\%, \text{ NPV } 61\% , P = .006) \). Objective PANSS insight was more predictive than Insight Scale at baseline and 6 weeks, though PANSS total was a better predictor at each of these stages.

Findings were very similar for first episode patients alone (available on request).

Discussion

Hypothesis 1 was largely supported: longitudinal modeling showed that Self-Esteem, Medication Attitudes, Need for Treatment, Objective, and Self-Reported Insight represented distinct but correlated constructs.

Hypotheses 2 and 3 were only partially supported. Although all latent variables were significantly correlated, Awareness of Illness scores emerged as most related to self-esteem. Paradoxically, falling latent self-esteem predicted greater Awareness of Illness at follow-up, but at each assessment point greater Awareness predicted higher Rosenberg scores. Perhaps the process of accepting the illness label was demoralizing, but those who had done so were then able to maintain a positive self-image. These findings, consistent across follow-up, add to existing models of self-stigmatization and insight.

Contrary to Hypothesis 2, insight separated into three latent variables (need for treatment, objective, and self-reported insight) not one. The separation of objective and self-reported insight on longitudinal modeling might have been due to initial symptom severity influencing assessors’ rating of insight, producing artifactual improvement as symptoms reduced. This is consistent with 6-week, not baseline, PANSS insight predicting readmission, whereas baseline BIS scores were most predictive.

Hypothesis 4 is relevant here. Most measures’ raw scores did not support it: of all included in the model only changes from baseline to 6 weeks in g12 and Relabeling Symptoms were significant (table 1). Other measures’ mean remained consistent despite considerable change in scores from visit to visit for individuals. Growth curve modeling, however, suggested that self-esteem and self-reported insight had, buried in this variation, underlying tendencies toward rapid initial improvement (however limited) that then slowed. This implies that aspects of insight and self-esteem are affected by the initial illness episode before returning to more trait-like behavior. Medication Attitudes did not show this, but DAI and Satisfaction were not measured over the initial phase of rapid improvement. This perhaps deflated Attitudes’ change variables correlations with other change variables (eg, Self-Esteem’s) because they did not cover this period of greater change. However, this highlights the association of insight-related with Attitude change variables, confirming them as important determinants of change (figure 2).

Modeling insight and concordance as predictors of outcome indicated that readmission and remission were relatively well predicted but not relapse, which may not have been as reliably detected. Despite this, poor self-reported insight during acute psychosis predicted relapse, unlike objective insight. This was consistent with the findings of Heinrichs et al\(^{108}\) that poor insight during relapse predicted readmission, arguably by impairing help seeking during relapse. The current finding could be explained by relapse somehow reinstating an earlier state of poor insight best detected by self-report. Readmission was substantially more likely in the 22% with the least insight (scores <6), suggesting that this very poor initial insight group segregates itself as having a particularly high likelihood of readmission (61% over 18 months compared with 27% for the rest of the cohort: see supplementary table 3).
On the other hand, PANSS insight after response was somewhat more predictive of outcome, arguably because objectively rated insight better reflected trait insight that influences ongoing concordance.71

Concordance (DAI) failed to predict remission, suggesting that adherence is necessary but insufficient, underlining another difference from insight. Other predictors include severity of illness and treatment response, as indicated by the performance of PANSS totals as predictors.

This cohort’s strength was its representativeness: recruited from consecutive presentations from defined catchments with a low refusal rate66 (13%) and the repeated assessments providing data from a short interval after admission (under 14 working days). Unfortunately, adherence itself was unmeasured. It was a limitation that second episode sufferers were included in order to provide sufficient participants, given the high noncompletion rate of the satisfaction measure and (to a lesser extent) the DAI in certain centers. However, sensitivity analyses showed good fit in the first episode patients. There were problems with missing data for some scales (the treatment satisfaction scale at 18 months, particularly, though this was remedied by its removal from the structural equation models), but these were largely explained by center differences that produced data “missing at random.”106 Sensitivity analysis removing centers with fewer completions showed that the models still fitted well and structural equation models fitted by full information maximum likelihood methods are relatively insensitive to this type of attrition. Depression was not included. Previous work in this cohort shows that it is not an important mediator of insight’s relationship with self-esteem.5

Implications for Interventions
In these models, change occurred rapidly without specific intervention in the early weeks of treatment, consistent with findings that good initial response drives adherence.58,68 This suggests that the extra impetus of intervention is best timed after this period. It should address attitudes to medication and knowledge of treatment without focusing on awareness of illness, which is intimately related to self-concept and likely to provoke resistance, whereas change in medication attitudes need not do so.

Rationale for Combining Online Psychoeducation, SMS Reminders, and Motivational Interviewing
The complexity of many successful interventions reveals that the interplay between different processes is often critical to intervention as well as understanding.2 This is the case for adherence interventions across a range of disorders: efficacious approaches are complex and include elements common to antipsychotic adherence interventions; none has a large effect on adherence or outcome.109 It is unsurprising that simple interventions for schizophrenia have poor efficacy: motivational interviewing alone fails to make it easier to take tablets, while reminders alone little affect attitudes. Meta-analysis by Pijnenborg et al110 of interventions improving psychotic insight found that simple interventions had moderate or small effect sizes (eg, psychoeducation—$d = 0.42, CI: −0.13, 0.98$; adherence therapy—$d = 0.26, CI: −0.23, 0.76$), but two studies of complex interventions had far larger effects ($d = 0.69, CI: −0.15, 1.23$). As discussed, individual characteristics that make natural, potentially synergistic, targets for intervention are attitudes to medication, insight into symptoms and the need for treatment, and neurocognitive deficits. Existing research indicates the feasibility and acceptability of three potential elements of a combined approach to them.

Motivational Interviewing  This has been a highly influential approach to changing attitudes in substance misuse treatment.113 Despite initial optimism,112 motivational approaches alone have not continued their success in chronic schizophrenia.113,114 They may not address enough of the complex causes of poor adherence alone110 or perhaps adherence measures are failing to capture improvement because in Kemp’s trial112 readmission reduced and in another trial by Schulz et al.114 symptoms improved. In early illness, a mirror image study showed reduction in relapse after therapy.115 On the other hand, the trial by Staring et al116 showed substantial improvement in adherence (but not insight), $d = 0.48$, after a complex intervention involving motivational interviewing for those with negative attitudes ($87\%$ of the participants) but with other techniques for those with poor response or those who were chaotic. One such technique is use of reminders.

SMS Reminders. Mobile phone–based “mHealth” approaches are natural in predominantly young early psychosis patients. Prompts may increase the proportion of psychosis sufferers attending clinic,117 including SMS reminders,118 which are capable of altering behavior across a range of disorders.119 Several studies have confirmed that SMS reminders are acceptable and feasible in schizophrenia sufferers.118,120 Spaniel et al121,122 showed an increase in adherence after automatic SMS texting was started (the Information Technology Aided Relapse Prevention in Schizophrenia [ITAREPS] system) in a mirror image design. An open randomized controlled trial of the ITAREPS system over a year in 45 Japanese schizophrenia sufferers found a just-significant decrease in hazard of relapse ($0.21, CI: 0.04, 0.99$), loosely defined, and a significant decrease in in-patient days from 88 to 19 days.123

Psychoeducation. This is an obvious need after first episodes. Although one meta-analysis found psychoeducation’s effect on insight was appreciable but not significant because of the small number of trials,110 another124 found
that psychoeducation improved adherence in the medium term and was likely to reduce relapse (relative risk, RR: 0.70, CI: 0.61, 0.81) and readmission (RR: 0.71; CI: 0.56, 0.89). Briefier interventions had less effect on nonadherence (RR: 0.63; CI: 0.41, 0.96) but no evidence of different effect on relapse (RR: 0.61; CI: 0.43, 0.89). Though using information technology to provide this education was less well supported, the review by Välimäki et al\textsuperscript{25} finds a significant decrease in the risk of nonadherence (RR: 0.45, CI: 0.27, 0.77) in one, probably open, randomized trial in 71 chronic sufferers.

Proposed Trial

Given the evidence concerning early adherence’s determinants and interventions, we proposed a combined intervention for a randomized controlled trial of a multimodal intervention within the OPTiMiSE program. The approach chosen includes SMS text reminders to take medication, psychoeducation by website, and motivational interviewing. Raters blind to allocation assess attitudes (DAI),\textsuperscript{79} knowledge (Knowledge About Psychosis Inventory\textsuperscript{126}), insight (Insight Scale\textsuperscript{102}), adherence (Compliance Rating Scale\textsuperscript{115}), symptoms (PANSS\textsuperscript{103}), and side effects at baseline, the end of the 6-week initial intervention, and after 3 months (after the final booster sessions) and 12 months. Relapse is the primary outcome and hospitalization a secondary one.

Supplementary Material

Supplementary material is available at http://schizophreniabulletin.oxfordjournals.org.

Funding

European Commission via the European Community’s Seventh Framework Programme (Grant Agreement HEALTH-F2-2010-242114).

Acknowledgments

We acknowledge support from Dr Richard Emsley, Lecturer in Biostatistics, University of Manchester, and Dr Ankur Khanna, Manchester Mental Health & Social Care NHS Trust. C.A. has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, Bristol-Myers Squibb, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Takeda, and Schering Plough. B.G. is the leader of a Lundbeck Foundation Center of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. She has nothing else to declare. In the last 3 years, S.L. has received honoraria for lectures from Abbvie, Bristol-Myers Squibb, ICON, EliLilly, Janssen, Johnson & Johnson, Roche, Sanofi-Aventis, Lundbeck, Servier, and Pfizer and for consulting/advisory boards from Roche, EliLilly, Medavante, Bristol-Myers Squibb, Janssen, Johnson & Johnson, and Lundbeck. EliLilly has provided medication for a study with S.L. as primary investigator. No other authors acknowledged a conflict of interest.

References


76. Lysaker PH, Roe D, Yanos PT. Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull. 2007;33:192–199.


98. Wiffen BD, Rabinowitz J, Lex A, David AS. Correlates, change and ‘state or trait’ properties of insight in schizophrenia. *Schizophr Res*. 2010;122:94–103.


104. SPSS. *SPSS and AMOS 20.0*. Chicago, IL: SPSS Inc.; 2009.


